Skip to content
myglp1coverage.com

BCBS Rhode Island · Weight Loss

BCBS Rhode Island coverage for Wegovy (Weight Loss)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
  • BMI of 23 or higher for patients of Asian descent
  • BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age >= 18 years
  • BMI >= 30 kg/m2

Adult overweight with comorbidity

All of:

  • Age >= 18 years
  • BMI >= 27 kg/m2

Plus any one of:

  • Hypertension
  • T2DM
  • dyslipidemia
  • OSA
  • CVD
  • MASH

Pediatric obesity (age 12+)

All of:

  • Age >= 12 years
  • BMI at or above 95th percentile for age and sex

Asian adult overweight/obesity

All of:

  • BMI >= 23 kg/m2 (South Asian, Southeast Asian, or East Asian adults)

Documentation to bring

  • Baseline BMI documentation
  • Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
  • Age documentation (>= 12 years for pediatric; >= 18 years for adult)

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: Document covers both Wegovy injection and Wegovy tablet formulations. Wegovy HD (high-dose semaglutide) is also listed as a separate formulation for weight loss in adults. Efficacy should be assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated. Pediatric patients aged 12+ with obesity (BMI >= 95th percentile) are included per FDA labeling.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, and MASH)
  • BMI of 23 or higher for patients of Asian descent
  • BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Adult obesity

All of:

  • Age >= 18 years
  • BMI >= 30 kg/m2

Adult overweight with comorbidity

All of:

  • Age >= 18 years
  • BMI >= 27 kg/m2

Plus any one of:

  • Hypertension
  • T2DM
  • dyslipidemia
  • OSA
  • CVD
  • MASH

Pediatric obesity (age 12+)

All of:

  • Age >= 12 years
  • BMI at or above 95th percentile for age and sex

Asian adult overweight/obesity

All of:

  • BMI >= 23 kg/m2 (South Asian, Southeast Asian, or East Asian adults)

Documentation to bring

  • Baseline BMI documentation
  • Documentation of weight-related comorbidity if BMI 27–29.9 kg/m2
  • Age documentation (>= 12 years for pediatric; >= 18 years for adult)

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Continuation recommended only for patients achieving at least 5% weight loss and tolerating therapy, assessed after 12 weeks at a therapeutic dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concomitant use with other semaglutide-containing products not recommended
  • Concomitant use with any other GLP-1 receptor agonist not recommended

Policy note: Document covers both Wegovy injection and Wegovy tablet formulations. Wegovy HD (high-dose semaglutide) is also listed as a separate formulation for weight loss in adults. Efficacy should be assessed after 12 weeks at therapeutic dose; continuation only if >= 5% weight loss achieved and therapy tolerated. Pediatric patients aged 12+ with obesity (BMI >= 95th percentile) are included per FDA labeling.

Policy effective May 4, 2026 · verified June 2, 2026 · source: RI_Weight_Management_ProgSum.pdf

All Wegovy policies under BCBS Rhode Island · Check your card